SHORT MINI-FUTURE - GENMAB | Delayed Deutsche Boerse AG 16:03:33 23/05/2024 BST | ||
| 30.83 EUR | +1.08% |
|
| Current month | -4.75% | ||
| 1 month | -0.75% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 23/05/24 | 30.83 | +1.08% |
| 22/05/24 | 30.5 | -1.90% |
| 21/05/24 | 31.09 | +1.53% |
| 17/05/24 | 30.62 | -0.13% |
| 16/05/24 | 30.66 | +1.22% |
Delayed Quote Deutsche Boerse AG
Last update May 23, 2024 at 04:03 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VU0EM3 |
| ISIN | DE000VU0EM33 |
| Date issued | 01/12/2022 |
| Strike | 4,340 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 15.75 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 33.6 € |
|---|---|
| Lowest since issue | 13.95 € |
| Spread | 0.49 € |
| Spread % | 1.56% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
2,055
DKK
Average target price
2,466
DKK
Spread / Average Target
+19.99%
- Stock Market
- Certificates
- Certificat
